David Taylor
Medical · Morehead City, NCNPI 1114488640
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $33,213 of the $40,321 with a category attached, or 82.4%. AbbVie accounts for 88.2% of it on its own, with 19 other manufacturers making up the rest. Among medical clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 423 payments — averaging $95.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$36K
- Teva Pharmaceuticals USA, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$600
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$590
- Neurocrine Biosciences, Inc.$490
- Sunovion Pharmaceuticals Inc.$478
- plus $1K from 14 others
What the payments were for
- Speaking & faculty fees$33,21382%
- Travel & lodging$1,0093%
- Food & beverage$5,53814%
- Education$5611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 132 | $35,559 |
| Teva Pharmaceuticals USA, Inc. | 80 | $1,155 |
| Otsuka America Pharmaceutical, Inc. | 32 | $600 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $590 |
| Neurocrine Biosciences, Inc. | 25 | $490 |
| Sunovion Pharmaceuticals Inc. | 28 | $478 |
| Vanda Pharmaceuticals Inc. | 13 | $282 |
| Johnson & Johnson | 11 | $228 |
| Lundbeck LLC | 11 | $220 |
| E.r. Squibb & Sons, L.L.C. | 12 | $178 |
| Alkermes, Inc. | 7 | $150 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $124 |
| Supernus Pharmaceuticals, Inc. | 5 | $94 |
| Corium, LLC | 4 | $42 |
| Tris Pharma Inc | 2 | $32 |
| Almatica Pharma LLC | 2 | $31 |
| Indivior Inc. | 1 | $21 |
| Neos Therapeutics, LP | 1 | $18 |
| Amgen | 1 | $15 |
| OWP Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$33,917
How this compares
$40,321 in reported general payments places this provider in the 95th percentile of 878 medical providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $172,324 |
| Invega SustennaPaliperidone Palmitate | 50 | $163,096 |
| Austedo XrDeutetrabenazine | 12 | $92,393 |
| VraylarCariprazine Hcl | 52 | $84,640 |
| RexultiBrexpiprazole | 37 | $59,476 |
| TrintellixVortioxetine Hydrobromide | 41 | $24,226 |
| Lurasidone Hcl | 78 | $7,609 |
| Lisdexamfetamine Dimesylate | 17 | $5,277 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $5,199 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 132 | $4,642 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 37 | $4,246 |
| Aripiprazole | 81 | $4,024 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 54 | $3,465 |
| Buspirone Hcl | 178 | $1,745 |
| Paliperidone ErPaliperidone | 11 | $1,453 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $490 | $172,32420 claims |
| Johnson & JohnsonInvega Sustenna | $228 | $163,09650 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,155 | $92,39312 claims |
| AbbVieVraylar | $35,559 | $84,64052 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $600 | $59,47637 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $124 | $29,42654 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 medical providers in North Carolina.
Other medical in Morehead City
- Lauren ThomasMorehead City$11K
- David HendersonMorehead City$10K
- James NorrisMorehead City$10K
- Grace McLaurinHickory$553K
- Joel ThompsonCharlotte$265K
- Virginia JethroCary$213K
- Payal Soni-PatelAsheville$76K
- William JarrettElkin$59K
- Amanda ZimmermanWinston Salem$48K
- Katherine CardSalisbury$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.